266 related articles for article (PubMed ID: 30131308)
1. CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas.
Guan X; Zhang C; Zhao J; Sun G; Song Q; Jia W
EBioMedicine; 2018 Sep; 35():233-243. PubMed ID: 30131308
[TBL] [Abstract][Full Text] [Related]
2. Autophagy-related CMTM6 promotes glioblastoma progression by activating Wnt/β-catenin pathway and acts as an onco-immunological biomarker.
Dai L; Xiao J; Li X; Tao Y; Zhou P; Lyu L; Shi Z; Liang X; Jia Z; Jiang S
J Gene Med; 2024 May; 26(5):e3685. PubMed ID: 38686653
[TBL] [Abstract][Full Text] [Related]
3. Novel roles of VAT1 expression in the immunosuppressive action of diffuse gliomas.
Yang P; Wang K; Zhang C; Wang Z; Liu Q; Wang J; Jiang T; Shan X
Cancer Immunol Immunother; 2021 Sep; 70(9):2589-2600. PubMed ID: 33576871
[TBL] [Abstract][Full Text] [Related]
4. LncRNA-PVT1 was identified as a key regulator for TMZ resistance and STAT-related pathway in glioma.
Chen Y; Ma F; Zhang Z; Guo Y; Shen H; Chen H
BMC Cancer; 2023 May; 23(1):455. PubMed ID: 37202742
[TBL] [Abstract][Full Text] [Related]
5. Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy.
Martinez-Morilla S; Zugazagoitia J; Wong PF; Kluger HM; Rimm DL
Oncoimmunology; 2020 Dec; 10(1):1864909. PubMed ID: 33457084
[TBL] [Abstract][Full Text] [Related]
6. CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1.
Miao B; Hu Z; Mezzadra R; Hoeijmakers L; Fauster A; Du S; Yang Z; Sator-Schmitt M; Engel H; Li X; Broderick C; Jin G; Gomez-Eerland R; Rozeman L; Lei X; Matsuo H; Yang C; Hofland I; Peters D; Broeks A; Laport E; Fitz A; Zhao X; Mahmoud MAA; Ma X; Sander S; Liu HK; Cui G; Gan Y; Wu W; Xiao Y; Heck AJR; Guan W; Lowe SW; Horlings HM; Wang C; Brummelkamp TR; Blank CU; Schumacher TNM; Sun C
Cancer Cell; 2023 Oct; 41(10):1817-1828.e9. PubMed ID: 37683639
[TBL] [Abstract][Full Text] [Related]
7. ARPC5 acts as a potential prognostic biomarker that is associated with cell proliferation, migration and immune infiltrate in gliomas.
Ming Y; Luo C; Ji B; Cheng J
BMC Cancer; 2023 Oct; 23(1):937. PubMed ID: 37789267
[TBL] [Abstract][Full Text] [Related]
8. The RPL4P4 Pseudogene Is a Prognostic Biomarker and Is Associated with Immune Infiltration in Glioma.
Wang Z; Aili Y; Wang Y; Maimaitiming N; Qin H; Ji W; Fan G; Li B
Oxid Med Cell Longev; 2022; 2022():7967722. PubMed ID: 35993018
[TBL] [Abstract][Full Text] [Related]
9. Classification of diffuse lower-grade glioma based on immunological profiling.
Wu F; Wang ZL; Wang KY; Li GZ; Chai RC; Liu YQ; Jiang HY; Zhai Y; Feng YM; Zhao Z; Zhang W
Mol Oncol; 2020 Sep; 14(9):2081-2095. PubMed ID: 32392361
[TBL] [Abstract][Full Text] [Related]
10. Molecular and clinical characterization of ANG expression in gliomas and its association with tumor-related immune response.
Wang J; Shan A; Shi F; Zheng Q
Front Med (Lausanne); 2023; 10():1044402. PubMed ID: 37928479
[TBL] [Abstract][Full Text] [Related]
11. CMTM6 as a potential therapy target is associated with immunological tumor microenvironment and can promote migration and invasion in pancreatic adenocarcinoma.
Gao H; Yin J; Guan X; Zhang S; Peng S; Liu X; Xing F
Funct Integr Genomics; 2023 Sep; 23(4):306. PubMed ID: 37726578
[TBL] [Abstract][Full Text] [Related]
12. GSDMA at the crossroads between pyroptosis and tumor immune evasion in glioma.
Zhang R; Song Q; Lin X; Du B; Geng D; Gao D
Biochem Biophys Res Commun; 2023 Dec; 686():149181. PubMed ID: 37924669
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis reveals that LTBR is a immune-related biomarker for glioma.
Tang Q; Yuan Y; Li L; Xu Y; Ji W; Xiao S; Han Y; Miao W; Cai J; You P; Chen M; Ding S; Li Z; Qi Z; Hou W; Luo H
Comput Biol Med; 2024 May; 174():108457. PubMed ID: 38599071
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic and prognostic significance of CMTM6 and PD-L1 expression in cervical squamous cell carcinoma.
Ma H; Shi S; Ma Z; Sun J; Liu X; Niu S; Liu H; Zhang Z
Int J Clin Exp Pathol; 2023; 16(12):368-377. PubMed ID: 38188349
[TBL] [Abstract][Full Text] [Related]
15. Glioma hexokinase 3 positively correlates with malignancy and macrophage infiltration.
Liang T; Zhou X; Wang Y; Ma W
Metab Brain Dis; 2024 Apr; ():. PubMed ID: 38687460
[TBL] [Abstract][Full Text] [Related]
16. Integrative analysis of bulk RNA-seq and scRNA-seq data indicates the prognostic and immunologic values of SERPINH1 in glioma.
Hou S; Chen Y; Jin C; Lin N
Environ Toxicol; 2024 Jun; 39(6):3654-3665. PubMed ID: 38506564
[TBL] [Abstract][Full Text] [Related]
17. Crosstalk of different cell-death patterns predicts prognosis and drug sensitivity in glioma.
Yu M; Huo D; Yu K; Zhou K; Xu F; Meng Q; Cai Y; Chen X
Comput Biol Med; 2024 Jun; 175():108532. PubMed ID: 38703547
[TBL] [Abstract][Full Text] [Related]
18. Distinct immune escape and microenvironment between RG-like and pri-OPC-like glioma revealed by single-cell RNA-seq analysis.
Xian W; Asad M; Wu S; Bai Z; Li F; Lu J; Zu G; Brintnell E; Chen H; Mao Y; Zhou G; Liao B; Wu J; Wang E; You L
Front Med; 2024 Feb; 18(1):147-168. PubMed ID: 37955814
[TBL] [Abstract][Full Text] [Related]
19. CMTM6: A Critical Prognostic Indicator in Non-Small Cell Lung Cancer.
Dai F; Duan YL; Feng Q; Song SL; Yang JL; Lv T
J Cancer; 2024; 15(8):2373-2379. PubMed ID: 38495487
[TBL] [Abstract][Full Text] [Related]
20. Expression and Clinical Significance of CMTM6 in Nonsmall Cell Lung Cancer.
Hou X; He S; Zhang D; Yang C; Shi Y; Zhang K
DNA Cell Biol; 2020 Oct; ():. PubMed ID: 33090010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
